The 24-Month Prognosis of Patients With Positive or Intermediate Results in the Intracoronary Ergonovine Provocation Test  by Shin, Dong IL et al.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 7 , 2 0 1 5
ª 2 0 1 5 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 4 . 1 2 . 2 4 9The 24-Month Prognosis of Patients
With Positive or Intermediate Results
in the Intracoronary Ergonovine
Provocation Test
Dong IL Shin, MD,* Sang Hong Baek, MD,y Sung Ho Her, MD,z Seung Hwan Han, MD,x Youngkeun Ahn, MD,k
Keun-Ho Park, MD,k Dong-Soo Kim, MD,{ Tae-Hyun Yang, MD,{ Dong-Ju Choi, MD,# Jung-Won Suh, MD,#
Hyuck Moon Kwon, MD,** Byoung Kwon Lee, MD,** Hyeon-Cheol Gwon, MD,yy Seung-Woon Rha, MD,zz
Sang-Ho Jo, MDxxABSTRACTFro
Ko
Un
Un
Ko
Se
Se
rep
MaOBJECTIVES This study was an observational, multicenter registry to determine clinical characteristics and 24-month
prognosis of patients who underwent intracoronary ergonovine provocation tests.
BACKGROUND The clinical characteristics and prognosis of patients who underwent the ergonovine provocation for
vasospastic angina were not fully elucidated.
METHODS A total of 2,129 patients in the VA-KOREA (Vasospastic Angina in Korea) registry were classiﬁed into positive
(n ¼ 454), intermediate (n ¼ 982), and negative (n ¼ 693) groups by intracoronary ergonovine provocation tests. The
24-month incidences of cardiac death, new-onset arrhythmia, and acute coronary syndrome were determined (mean 26.7
 8.8 months).
RESULTS The number of smokers, frequency of angina before angiography, high-sensitivity C-reactive protein, and
triglyceride were higher in the positive group than in other groups. The clinical characteristics of the intermediate and the
negative groups were very similar. In the positive group, the incidences of diffuse, focal, and mixed spasm were 65.9%,
23.6%, and 10.6%. Coronary spasm was more frequently provoked on atherosclerotic segments. The 24-month inci-
dences of cardiac death, arrhythmia, and acute coronary syndrome were low (0.9%, 1.6%, and 1.9%, respectively) in the
positive group, and there was no cardiac death in the intermediate group (p ¼ 0.02). In the positive group, frequent
angina, current smoking, and multivessel spasm were independent predictors for adverse events.
CONCLUSIONS The 24-month prognosis of the positive group in the intracoronary ergonovine provocation test was
relatively worse than that of the intermediate group. More intensive clinical attention should be paid to vasospastic
angina patients with high-risk factors including frequent angina before angiography, current smoking, and multivessel
spasm. (J Am Coll Cardiol Intv 2015;8:914–23) © 2015 by the American College of Cardiology Foundation.C oronary spasm has been recognized as animportant pathophysiology of myocardialischemia in patients with or without coro-
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AB BR E V I A T I O N S
AND ACRONYM S
CAG = coronary angiography
CCB = calcium-channel blocker
ECG = electrocardiography
JCSA = Japanese Coronary
Spasm Association
LCA = left coronary artery
MI = myocardial infarction
RCA = right coronary artery
= vasospastic angina
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915in Korea and Japan (1–4). Thus, VSA is regarded as one
of the crucial functional coronary diseases, particu-
larly in the East Asian countries (4,5).
In Japan, a number of studies have elucidated
the pathogenesis, diagnosis, and characteristics of
VSA (6,7). Moreover, the nationwide registry of the
Japanese Coronary Spasm Association (JCSA) has
established the clinical prognostic factors, such as
out-of-hospital cardiac arrest and mixed-type spasm
(8,9). Furthermore, the JCSA risk score was recently
suggested for the comprehensive risk assessment
and prognostic stratiﬁcation of VSA patients (4).SEE PAGE 924Many study groups in Korea have reported the
clinical ﬁndings, prognostic factors, and possible new
pharmacologic agents for Korean VSA patients with
variable provocation methods (10–12). However, there
have been few demographic reports so far from the
large-scale analysis of Korean patients who under-
went intracoronary ergonovine provocation tests.
Moreover, most of the previous studies have not only
included a small number of patients, but also applied
different diagnostic methods and diverse criteria for
the deﬁnition of VSA.
Consequently, we conducted a large-scale, multi-
center registry for VSA patients who had been tested
with the same provocation protocol using only intra-
coronary ergonovine. We also determined the clinical
characteristics, prognosis, and associated risk factors
in each of the groups of patients who were classiﬁed
according to results of the ergonovine provocation.
METHODS
STUDY SUBJECTS. VA-KOREA (Vasospastic Angina
in KOREA) is a prospective, observational, and
web-based registry of clinical, angiographic, and
prognostic data from patients who underwent intra-
coronary ergonovine provocation tests. Patients who
had suspicious symptoms and underwent coronary
angiography (CAG) with the ergonovine provocation
test according to the clinician’s decision were
included. A total of 2,174 patients who underwent the
ergonovine provocation test were consecutively
entered into the registry from May 2010 to November
2013 in 11 cardiovascular centers and selected as the
study subjects. All participated centers have per-
formed high-volume CAG (>1,800 cases/year) and
percutaneous coronary intervention (PCI) (>500
cases/year) and have used the same study protocol for
the intracoronary ergonovine provocation test.
All of the registered patients had normal ﬁndings
or minimal (<50% luminal diameter narrowing)atherosclerosis at the baseline CAG, whereas
those with signiﬁcant atherosclerosis ($50%
luminal diameter narrowing) were excluded.
Patients with renal failure on continuous
dialysis, known malignant or inﬂammatory
diseases, and catheter-induced spasm at
the baseline CAG were also excluded. All pa-
tients who showed positive results on their
provocation tests or deﬁned spontaneous
spasm received medical treatments including
CCBs and other vasodilators during the
follow-up. Medications for nonpositive sub-
jects were prescribed on the basis of the clinician’s
decision.
There was no industry involvement, and all pa-
tients gave their written informed consent. All of the
surveys were approved by the institutional review
board of each participating institution.
CAG AND PROVOCATION TEST FOR VSA. VSA was
diagnosed on the basis of the criteria in the Guide-
lines for Diagnosis and Treatment of Patients with
Vasospastic Angina of the Japanese Circulation Soci-
ety (13). The baseline CAG was performed for the right
coronary artery (RCA) and then the left coronary ar-
tery (LCA), respectively. Intracoronary infusion of
ergonovine was used for the provocation test. Incre-
mental doses of 20 (E1), 40 (E2), and 60 mg (E3) were
injected into the LCA. If coronary spasm was not
provoked on the LCA, incremental doses of 10 (E1), 20
(E2), and 40 mg (E3) were injected into the RCA (9).
Once spasm was provoked, intracoronary nitrate was
injected. The vasoactive drugs were discontinued at
least 48 h before CAG.
The deﬁnition of a positive result was total or
subtotal (>90% luminal diameter narrowing) occlu-
sion accompanied by ischemic symptoms and/or
electrocardiographic (ECG) changes (the positive
group) (13). Patients who showed spontaneous total
or subtotal coronary spasm on their baseline CAG
resolved by nitrate were also included in the posi-
tive group. The deﬁnition of a negative result
was <50% luminal narrowing without ischemic
symptoms and ECG changes (the negative group).
Additionally, we deﬁned intermediate constriction
as 50% to 90% luminal narrowing with or without
ischemic symptoms and/or ECG changes (the inter-
mediate group). All of the vascular responses to
ergonovine in the provocation test and atheroscle-
rosis on the baseline CAG were quantitatively
analyzed for epicardial coronary artery diameters
$2.5 mm by clinicians unaware of patient status at
the core laboratory of Seoul St. Mary’s Hospital,
Seoul, South Korea.
VSA
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916DEFINITIONS AND ENDPOINTS. An ischemic ECG
change was deﬁned as an ST-segment elevation or
depression >0.1 mV or a negative U-wave in at least 2
related leads (2). A multivessel spasm was deﬁned as
a positive spasm in more than 2 major ($2.5 mm)
epicardial coronary arteries (2,12). The types of
spasm were classiﬁed into focal, diffuse, and mixed
types. The focal type was deﬁned as a discrete spasm
localized in 1 coronary segment, whereas the spasm
observed continuously from the proximal to the distal
segments was regarded as the diffuse type. The
mixed type was deﬁned as the multivessel spasm in
which at least 1 coronary artery had focal spasm, and
the other had diffuse spasm (9). Cardiac death was
deﬁned as any death due to a proximate cardiac cause
such as myocardial infarction (MI), low-output fail-
ure, fatal arrhythmia, and death from unknown cau-
ses (2). MI was deﬁned as “detection of a rise and/or
fall of cardiac biomarker values with at least one
value above the 99th percentile upper-reference limit
and with at least one of the following: ischemia
symptoms, new signiﬁcant ST-T changes, or new left
bundle branch block, development of pathological Q
in the ECG, imaging evidence of new loss of viable
myocardium or regional wall motion abnormality,
identiﬁcation of a thrombus by CAG” (14). Patients
who presented with clinically-signiﬁcant arrhythmia,
including atrial or ventricular tachycardia/ﬁbrillation,
symptomatic premature beats, sick-sinus rhythm,
and atrioventricular block, for the ﬁrst time during
the follow-up were considered to have the new-onset
arrhythmia (15). The routine ECG was checked during
the regular or emergent visits, and 24-h Holter
monitoring was also performed in patients with sus-
picious symptoms. We also deﬁned medication
changes as adding drugs to the existing prescription
or switching more than 1 drug due to repeated angina.
The frequency of angina before angiography was
presented according to the prior classiﬁcation: grade
I: near-daily attacks; II: $4 attacks/month; III: $1
but <4 attacks/month; and IV: <1 attack/month (16).
The primary endpoint was a composite of cardiac
death, new-onset arrhythmia, and acute coronary
syndrome. The 12- and 24-month incidences of each
adverse event were also analyzed as the secondary
endpoints. Additionally, the incidence of repeated
angina leading to medication changes or rehospital-
ization, including emergency department visits, was
estimated in this analysis. All adverse events of
interest were conﬁrmed through the source docu-
ments, including medical records as well as tele-
phone interviews, and were also adjudicated by
the Local Events Committee of Seoul St. Mary’s
Hospital.STATISTICAL ANALYSIS. Continuous variables are
expressed as mean  SD and compared with the
analysis of variance. The Sheffe test was also per-
formed for the post-hoc analysis. Categorical vari-
ables are presented as numbers and percents. The
chi-square test or Fisher exact test was used for the
categorical variables. The incidences of the endpoints
in the positive and the intermediate groups were
estimated at 12 and 24 months and are displayed
with tables and Kaplan-Meier curves. The log-rank
test was performed to compare the incidences of the
endpoints between the 2 groups. To assess the center
variance component, we performed the additional
log-rank test by adding the center variable as the
strata variable. Additionally, the Cox regression
analysis was performed to identify the independent
predictors of the adverse events in the positive group.
The hazard ratio (HR) and the 95% conﬁdence inter-
val (CI) were also calculated. Values of p < 0.05 were
considered statistically signiﬁcant. The statistical
analyses were performed using SPSS version 18.0
software (SPSS, Chicago, Illinois).
RESULTS
PATIENT ENROLLMENT AND FOLLOW-UP. A total of
2,174 patients were registered in VA-KOREA. Forty-
ﬁve patients were excluded due to signiﬁcant
atherosclerosis on their baseline CAG (n ¼ 33) and due
to the other exclusion criteria (n ¼ 12). Thus, a total of
2,129 patients (97.9%) were analyzed: 454 (21.3%) in
the positive group, 982 (46.1%) in the intermediate
group, and 693 (32.6%) in the negative group. The
follow-up data for determining the 24-month prog-
nosis were available in 432 patients (95.2%) in the
positive group and 668 patients (68.0%) in the in-
termediate group. The mean follow-up duration was
26.7  8.8 months.
BASELINECLINICALANDLABORATORYCHARACTERISTICS.
The numbers of current smokers and males and the
frequency of angina before CAG were higher in the
positive group than in the 2 other groups. The base-
line clinical characteristics of the intermediate group
were very similar to those of the negative group
(Table 1).
The positive group showed higher levels of base-
line high-sensitivity C-reactive protein and triglycer-
ide than the 2 other groups. Although the level of
triglyceride in the intermediate group was higher
than in the negative group, other laboratory ﬁndings
were similar between the 2 groups (Table 2).
ANGIOGRAPHIC CHARACTERISTICS IN THE POSITIVE
GROUP. The positive rate of the ergonovine provo-
cation in our registry was 21.3%. The angiographic
TABLE 1 Baseline Clinical Characteristics
Positive
(n ¼ 454)
Intermediate
(n ¼ 982)
Negative
(n ¼ 693) p Value
Age, yrs 56.1  10.5 55.2  11.8 55.0  12.8 0.44
Male 315 (69.4) 349 (35.5) 283 (40.9) <0.001
Body mass index, kg/m2 25.0  3.3 25.6  4.8 24.6  3.5 0.21
Blood pressure, mm Hg
Systolic 137.3  18.6 132  17.4 134.1  18.8 0.09
Diastolic 78.0  12.1 75.8  13.4 76.4  12.1 0.07
Frequency of angina before angiography 0.03
I/II 70 (15.4)/139 (30.6) 44 (4.5)/168 (17.1) 26 (3.8)/111 (16.0)
III/IV 142 (31.3)/103 (22.7) 508 (51.7)/262 (26.7) 324 (46.8)/232 (33.5)
Risk factors of coronary artery disease
Hypertension 198 (43.6) 398 (40.5) 285 (41.1) 0.13
Diabetes 138 (30.4) 318 (32.4) 214 (30.9) 0.48
Current smoking 218 (48.0) 205 (20.9) 148 (21.4) <0.001
Dyslipidemia 71 (15.6) 166 (16.9) 107 (15.5) 0.56
Family history of coronary artery disease 23 (5.1) 67 (6.8) 50 (7.3) 0.47
Values are mean  SD or n (%).
TABLE 2 Baseline Laboratory Characteristics
Positive
(n ¼ 454)
Intermediate
(n ¼ 982)
Negative
(n ¼ 693) p Value
Post-Hoc
1: Positive
2: Intermediate
3: Negative
FBG, mg/dl 110.8  36.2 114  30.1 108.5  36.8 0.64
Cr, mg/dl 1.2  0.8 1.3  0.8 1.2  0.4 0.38
Troponin I, ng/ml 0.3  1.2 0.4  1.8 0.2  1.3 0.29
CK-MB, mg/dl 6.0  18.4 7.1  17.3 4.3  11.9 0.22
hsCRP, mg/l 1.1  0.2 0.7  0.6 0.6  0.4 0.03 1>2,3
NT-proBNP, pg/ml 166.5  300.1 146.0  265.3 180.7  847.5 0.42
Lipid proﬁle, mg/dl
Total cholesterol 194.2  36.1 208.8  44.5 205.8  36.3 0.29
Triglyceride 151.8  98.6 145.3  116.6 129.3  86.1 0.02 1>2>3
HDL cholesterol 45.5  11.7 48.8  13.7 48.3  12.8 0.02 1<2,3
LDL cholesterol 111.6  28.2 109.1  31.7 107.0  31.1 0.67
Thyroid function* 0.55
Normal 159 (61.9) 253 (60.7) 251 (64.2)
Hyper-/hypo- 8 (3.1)/12 (4.7) 16 (3.8)/21 (5.0) 12 (3.1)/15 (3.8)
Others 78 (30.4) 127 (30.5) 113 (28.9)
Cardiac function
LVEF, % 58.1  6.6 58.3  7.2 60.2  6.5 0.79
Mitral E/E0 10.5  4.7 11.9  5.9 11.3  6.7 0.74
Values are mean  SD or n (%). *Thyroid function tests were performed in 257 patients in the positive group,
417 patients in the intermediate group, and 391 patients in the negative group.
CK-MB ¼ creatine kinase-MB; Cr ¼ creatinine; FBG ¼ fasting blood glucose; HDL ¼ high-density lipoprotein;
hsCRP ¼ high-sensitivity C-reactive protein; LDL ¼ low-density lipoprotein; LVEF ¼ left ventricular ejection
fraction; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide.
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917characteristics in the positive group are presented in
Table 3. Single-vessel spasm was seen in 326 patients
(71.8%) and multivessel spasm in 128 (28.2%). Coro-
nary spasm was most frequently provoked on the RCA
(57.7%) in the patients with single-vessel spasm. In
the patients with multivessel spasm, 61 (47.7%) had
simultaneous spasm on their left anterior descen-
ding and left circumﬂex arteries. In single-vessel
spasm, the prevalence rates of diffuse and focal
spasm were 72.4% (n ¼ 236) and 27.6% (n ¼ 90).
In multivessel spasm, the mixed type was observed
in 48 (37.5%), the diffuse type in 63 (49.2%), and
the focal type in 17 patients (13.3%). Coronary
spasmwas more frequently provoked on the segments
with minimal atherosclerosis (365 segments, 57.6%)
than on the segments without minimal stenosis
(Table 3). The distributions of minimal atherosclerosis
and coronary spasm are presented in Figure 1.
MEDICAL TREATMENTS. In the positive group, CCBs
was prescribed in 428 patients (94.3%) and diltiazem
was the most frequently prescribed (221 patients,
51.6%). In addition, long-acting vasodilators in-
cluding nitrates, statins, and aspirin were used in
232 (51.1%), 178 (39.2%), and 172 patients (37.9%),
respectively. However, the use of beta-blockers
was limited to 11 patients (2.4%, 8 patients for heart
failure and 3 for other conditions). Most patients
in the positive group (n ¼ 383, 84.4%) received
combination-drug therapy, and CCBs plus nitrate was
the most frequently prescribed (n ¼ 145, 37.9%). In
the intermediate group, medications were prescribed
only for 223 patients (22.7%), and single therapy of
nitrate was the most frequent (n ¼ 142, 63.7%).FOLLOW-UP AND CLINICAL OUTCOMES IN THE
POSITIVE AND INTERMEDIATE GROUPS. Although
continuous medical treatments were strongly rec-
ommended for the patients to whom medications
were initially prescribed, 405 patients (93.8%) in
the positive group and 108 patients (48.4%) in
TABLE 3 Results of Angiographic Provocation Test in the Positive Group
(n ¼ 454)
Single-vessel spasm 326 (71.8)
Left main 0 (0)
LAD 103 (31.6)
Diagonal 2 (0.6)
LCx 30 (9.2)
OM 3 (0.9)
RCA 188 (57.7)
Multivessel spasm 128 (28.2)
LAD þ LCx 61 (47.7)
LAD þ RCA 8 (6.3)
LAD þ diagonal 22 (17.2)
LCx þ OM 11 (8.6)
LAD þ LCx þ diagonal 10 (7.8)
LAD þ LCx þ OM 8 (6.3)
Others 8 (6.3)
Type of spasm
Diffuse 299 (65.9)
Focal 107 (23.6)
Mixed 48 (10.6)
Ergonovine dose on spasm provocation
E1/E2/E3 162 (35.7)/192 (42.3)/100 (22.0)
ST-segment change in provocation of spasm
Elevation/depression 133 (29.3)/141 (31.1)
Elevation þ depression/no change 96 (21.1)/84 (18.5)
Main symptom in provocation of spasm
Chest pain/others/no symptom 305 (67.2)/91 (20.0)/58 (12.8)
Spontaneous spasm 76 (16.7)
Myocardial bridge on spastic segments 21 (4.6)
Association with minimal atherosclerosis*
Spasm on atherosclerotic segment 365 (57.6)
Spasm on nonatherosclerotic segment 269 (42.4)
Values are n (%). *Total 634 segments of coronary spasm.
LAD ¼ left anterior descending artery; LCx ¼ left circumﬂex artery; OM ¼ obtuse marginal
artery; RCA ¼ right coronary artery.
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continuously at the end of the follow-up.
In the positive group, 127 patients (29.4%) had
repeated angina leading to medication changes or
rehospitalization, whereas only 47 patients (12.1%)
experienced repeated angina in the intermediate
group (Table 4). The prevalence rates of new-onset
arrhythmia and acute coronary syndrome were very
low in both groups (1.6%vs. 0.6%, p¼0.13; and 1.9%vs.
0.6%, p ¼ 0.34, respectively). The rate of cardiac death
during the follow-up was very low in the positive
group (n¼4, 0.9%), whereas no cardiac death occurred
in the intermediate group (p ¼ 0.02) (Table 4). The
detailed characteristics of the patients with cardiac
death are presented in Table 5. The Kaplan-Meier
curves for the primary endpoint and each adverse
event are shown in Figures 2 and 3.
In the Cox regression analysis, the frequency of
angina I/II before CAG (HR: 1.46 [95% CI: 0.87 to2.04], p ¼ 0.02), current smoking (HR: 3.62 [95% CI:
1.17 to 7.39], p ¼ 0.001), and multivessel spasm (HR:
1.81 [95% CI: 1.21 to 3.78], p ¼ 0.01) were revealed as
the independent predictors of all adverse events in
the positive group.
DISCUSSION
The incidence, clinical characteristics, medical
treatment, 24-month clinical outcomes, and asso-
ciated risk factors in the VSA patients diagnosed
via intracoronary ergonovine provocation were re-
ported from the VA-KOREA registry. To the best of
our knowledge, this is the ﬁrst large-scale, multi-
center report on homogenous subjects who under-
went only the intracoronary ergonovine provocation
test. Additionally, the clinical characteristics and
24-month prognosis of the patients with interme-
diate constriction were novel and demonstrated
helpful information for the clinical characteristics of
the patients who underwent the ergonovine provo-
cation test.
Although several diagnostic methods for VSA
have been introduced, angiographic provocation
with acetylcholine or ergonovine is most often used
(7,9,10). Acetylcholine-induced coronary spasm may
be the combined effects of endothelial dysfunction
and vascular smooth muscle hyperconstriction (17,18).
However, ergonovine-induced spasm may predom-
inantly reﬂect endothelium-independent smooth
muscle hyperconstriction, although its effect could
be aggravated by endothelial dysfunction (19,20).
Because of its long half-life, ergonovine-induced
spasm is less likely to resolve spontaneously. Addi-
tionally, simultaneous spasm on the RCA and LCAmay
not be evaluated through the routine administration of
ergonovine, because nitrate should be infused in the
spasm-induced artery, and then spasm cannot be
provoked in the other artery (9,17,21). With all of the
faults of the ergonovine provocation test, however, it
is still widely used in Korea and Japan (2,4,8,9).
Recently, JCSA reported the safety of the ergonovine
provocation test, compared with the acetylcholine
provocation. Although both agents showed the
acceptable level of safety, acetylcholine had a signiﬁ-
cantly higher incidence of test-related ventricular
arrhythmia (9). In our registry, considering the clini-
cians’ concerns over the potential risk of arrhythmia
during the provocation and the unity of the mecha-
nism of the provoked spasm in the subjects, we
decided to use only ergonovine, not acetylcholine.
Additionally, acetylcholine is not commercially avail-
able in Korea. Thus, this analysis had great merit for
the homogenous subjects who underwent the VSA
FIGURE 1 Distribution of Minimal Atherosclerosis and Coronary Spasm
Minimal atherosclerosis was founded on 454 segments in the baseline angiography (A),
whereas coronary spasm was provoked on 634 segments (B). LAD ¼ left anterior
descending; LCx ¼ left circumﬂex; LM ¼ left main; OM ¼ obtuse marginal; RCA ¼ right
coronary artery.
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919provocation test using intracoronary ergonovine, not
acetylcholine, under the same criteria for the positive
result.
The degree of coronary constriction in response
to ergonovine may vary, and a certain degree of
nonspeciﬁc vasoconstriction could be shown in all
individuals receiving ergonovine (20,22). Although
total or subtotal occlusion was generally considered
to be a positive response in the ergonovine provoca-
tion (2,4,8,9,13), some study groups have deﬁned 75%
or even 50% narrowing as a positive response (23).
Thus, there has been no clear deﬁnition of the posi-
tive response to ergonovine, and it still remains un-
clear if hyper-responsiveness to ergonovine and VSA
are essentially the same phenomena. Kashima et al.
(24) suggested that patients with ergonovine-induced
intermediate constriction might show a false negative
response to ergonovine, so careful treatment should
be continued (24). However, Sunagawa et al. (23) re-
ported that the clinical characteristics of the patients
who demonstrated intermediate constriction in the
ergonovine provocation were similar to those of the
patients with negative results rather than to those
of the VSA patients (23). In our analysis, we also
demonstrated that the clinical and laboratory ﬁnd-
ings in the intermediate group were similar to those
in the negative group rather than the positive group.
Moreover, the intermediate group had signiﬁcantly
lower rates of cardiac death and rehospitalization
than the positive group despite the high rate of
medication withdrawal. It has been well known that
withdrawal of medication is the most important pre-
dictor for cardiac death in VSA patients (2). Our re-
sults could indicate the clinical differences betweenTABLE 4 12- and 24-Month Cumulative Outcomes in the Positive and Intermediate Groups
12 months 24 months
p Value
(Log-Rank)
Adjusted p Value*
(Log-Rank)
Positive
(n ¼ 432)
Intermediate
(n ¼ 668)
Positive
(n ¼ 432)
Intermediate
(n ¼ 668)
Primary endpoint† 14 (3.2) 6 (0.9) 17 (3.9) 8 (1.2) 0.04 0.02
Arrhythmia 5 (1.2) 2 (0.3) 7 (1.6) 4 (0.6) 0.13 0.49
VT/VF 0 (0) 0 (0.0) 1 (0.2) 0 (0.0)
Atrial ﬁbrillation 0 (0) 1 (0.1) 1 (0.2) 1 (0.1)
AV block 3 (0.7) 0 (0.0) 3 (0.7) 1 (0.1)
Others 2 (0.5) 1 (0.1) 2 (0.5) 2 (0.3)
Acute coronary syndrome 7 (1.6) 4 (0.6) 8 (1.9) 4 (0.6) 0.34 0.10
STEMI 0 (0) 0 (0.0) 0 (0) 0 (0.0)
NSTEMI/unstable angina 7 (1.6) 4 (0.6) 8 (1.9) 4 (0.6)
Cardiac death 3 (0.7) 0 (0.0) 4 (0.9) 0 (0.0) 0.02 0.03
Medication change 51 (11.8) 7 (3.1)‡ 68 (15.7) 17 (7.6)‡ 0.06 0.08
Rehospitalization/ED visit 44 (10.2) 24 (3.6) 59 (13.7) 30 (4.5) 0.04 0.01
Values are n (%). *Adjusted by the center variance component. †The primary endpoint was a composite of cardiac death, new-onset arrhythmia, and acute coronary syndrome.
‡The rate of medication change was estimated in 223 patients of the intermediate group who had the initial medications prescribed.
AV ¼ atrioventricular; ED ¼ emergency department; NSTEMI ¼ non–ST-segment elevation myocardial infarction; STEMI ¼ ST-segment elevation myocardial infarction; VF ¼
ventricular ﬁbrillation; VT ¼ ventricular tachycardia.
FIGURE 2 Kaplan-
The primary endpoin
coronary syndrome.
TABLE 5 Detailed Characteristics of the VSA Patients With Cardiac Deaths
Sex/Age (yrs)
Current
Smoking DM/HTN LVEF (%)
Type of
Spasm MS Involved Vessel Beta-Blocker Medication D-1* D-2†
JCSA
Score
1 Male/59 Yes No/no 58 Diffuse No LAD No Continuous 11 4
2 Male/65 Yes No/yes 46 Mixed Yes LAD þ LCx Yes Discontinue 6 7 8
3 Male/67 Yes Yes/no 66 Mixed Yes LAD þ RCA No Discontinue 4 6 6
4 Female/61 Yes Yes/no 43 Diffuse No RCA Yes Discontinue 3 6 6
*D-1 is deﬁned as the duration of medical treatments (months). †D-2 is deﬁned as the duration from discontinuation of medication to cardiac deaths (months).
DM ¼ diabetes mellitus; HTN ¼ hypertension; LVEF ¼ left ventricular ejection fraction; MS ¼ multivessel spasm; VSA ¼ vasospastic angina.
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920intermediate vasoconstriction and true VSA, and also
emphasize the need for strict positive criteria in the
ergonovine provocation test. However, there may be
several confounding factors in the rate of rehospital-
ization due to repeated angina. Although the fre-
quency and severity of angina in the intermediate
group could be less severe than those in the positive
group, the effect of the differences in the medical
treatments could also have played an important role
in the different rate of rehospitalization. Addition-
ally, repeated angina is a subjective symptom rather
than an objective sign inﬂuenced by different per-
sonal traits such as the pain threshold. Therefore,
the deﬁnite clinical meanings of the intermediate
constriction could still be open to debate (23,24).
Further larger-scale studies on the clinical features of
intermediate constriction should be conducted.
There have been a few reports for the prognosis of
patients who demonstrated the negative result in theMeier Curve for the Primary Endpoint
t was a composite of cardiac death, new-onset arrhythmia, and acuteergonovine provocation. Although they showed lower
incidences of recurrent angina, MI, and cardiac death
compared with those with ergonovine-induced VSA
in previous Japanese and European retrospective
studies (24,25), the negative groups in their studies
might include the intermediate group in our analysis.
Thus, the clinical outcomes of the true negative group
in the ergonovine provocation are still unclear. The
protocol of the VA-KOREA recommended regular
follow-up in the negative group to address this issue,
although medications were not prescribed. However,
the follow-up rate was too low to analyze the
24-month prognosis. In our analysis, the 1-month
follow-up rate was 66.2% (n ¼ 459), but the 12- and
24-month follow-up rates were only 15.4% (n ¼ 107)
and 3.2% (n ¼ 22), respectively, which was most likely
due to the lack of symptoms. Only 1 patient in
the negative group showed deﬁned new-onset
arrhythmia (atrial ﬁbrillation) at 9 months of follow-
up. However, it could not indicate the precise clin-
ical prognosis of the negative group due to the low
follow-up rate, and consequently, we could not pre-
sent the 24-month prognosis in the negative group.
We demonstrated that the high frequency of
angina before CAG, current smoking, and multivessel
spasm were independent predictors of worse out-
comes in VSA patients, consistent with the results of
previous studies (2,3,6,12). In Japan, JCSA recently
suggested a prognostic scoring system for VSA that
consists of 7 predictors for adverse cardiovascular
events (4). Because the VA-KOREA had already been
designed before the score was introduced, we did not
include several values of the scoring system. Specif-
ically, we excluded the patients with signiﬁcant
organic stenosis on their baseline CAG. It has been
noted that VSA patients without signiﬁcant stenosis
have an excellent long-term prognosis (12). Never-
theless, in our analysis, 75% of the patients who
experienced cardiac death had been assigned to the
high-risk group of the JCSA system, which could
imply the possibility of effectively applying this score
to Korean VSA patients in a further analysis. Mean-
while, the JCSA score did not include discontinuation
FIGURE 3 Kaplan-Meier Curves for Each Adverse Event
The 24-month event-free survival rates for new-onset arrhythmia (A), acute coronary syndrome (B), and cardiac death (C) were 98.2%, 98.0%, and 99.0%, respec-
tively, in the positive group. There was no cardiac death in the intermediate group.
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921of medications as a predictive factor, and it was not
revealed as an independent factor of adverse events
in our analysis, although 75% of the patients who
experienced cardiac death had discontinued medica-
tions. However, the JCSA score was derived from the
subjects for whom appropriate medications including
CCBs (93.0%) were continuously prescribed. Simi-
larly, most of the VSA patients (93.8%) in our registry
had also continuously taken $1 medication. Thus, in
further studies, the JCSA score should be applied on
the premise that patients with VSA should receive
adequate medical treatment.
To generalize our results in other settings without
a clinical interest in VSA, there are many factors to
consider. However, our results were from the analysis
in patients who underwent the angiographic ergono-
vine provocation test under the clearly-deﬁnedprotocol in the cardiovascular centers that had the
proactive clinical interest for VSA. Our results could
suggest the values of the clinical interest and the
proactive angiographic investigation for VSA under
the well-deﬁned homogenous protocol. In our regis-
try, the positive rate of the ergonovine provocation
test was 21.3%, similar to those of the previous re-
ports using the ergonovine provocation (12,20). The
incidence of VSA seems to be decreasing globally,
probably due to the use of CCBs and fewer smokers
(2,17). Thus, interest in organic stenosis and coronary
intervention is growing among cardiologists and
less attention is being paid to VSA. Additionally,
recent technological advances have driven the
increasing use of noninvasive diagnostic methods for
coronary artery diseases. Therefore, under these cir-
cumstances, fewer cardiologists may pay attention to
PERSPECTIVES
WHAT IS KNOWN? We determined the 24-month
clinical prognosis of Korean patients with positive
or intermediate results in intracoronary ergonovine
provocation tests for VSA.
WHAT IS NEW? The clinical characteristics and the
incidences of cardiac death, new-onset arrhythmia,
acute coronary syndrome, and repeated angina were
estimated. Patients with intermediate coronary
constriction demonstrated better 24-month clinical
outcomes than those with VSA, which suggests that
the homogenous strict positive criteria in the ergo-
novine provocation test should be established to
distinguish true VSA from hyper-responsiveness
to ergonovine. In addition, more intensive clinical
attention should be paid to VSA patients with high
risk factors including frequent angina before angi-
ography, current smoking, and multivessel spasm.
WHAT IS NEXT? The prospective, international,
multicenter registry and a prospective, randomized
controlled clinical study would be helpful in providing
the right answers to the many unsolved questions
about VSA in real evidence-based medicine.
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922VSA (17). However, VSA is still prevalent (2–5) and
may be refractory to conventional medications
(6,11,17). Thus, it could be important for clinicians not
only to have greater interest in VSA, but also to
conduct a larger-scale analysis of the clinical and
pathologic characteristics of VSA.
STUDY LIMITATIONS. First, this was an observational
registry study, which has inherent limitations. Sec-
ond, we could not clearly explain the precise causes
of the low follow-up rate and the relatively high rate
of medication withdrawal in the intermediate group.
However, given the lower rate of rehospitalization
due to repeated angina in the intermediate group
compared with the positive group, the severity of
angina might be an explanation for those rates.
Additionally, a deﬁnite treatment plan for the inter-
mediate constriction could not be suggested. Third,
the mean follow-up duration was only about 2 years.
Considering the few adverse events, a longer follow-
up period could be helpful in estimating the clinical
outcomes of VSA. Finally, we could not address
several novel issues in VSA, including the tissue
characterization, the effect of risk factor modiﬁca-
tion, and speciﬁc ECG changes. Moreover, although
the association between VSA and the progression of
atherosclerosis leading to PCI has been regarded as a
controversial issue, we could not present the data to
address this association. Thus, we are planning to
conduct new analyses to address these important is-
sues. Despite these limitations, this analysis could
provide helpful information for understanding the
clinical features of patients who underwent the
ergonovine provocation test.
CONCLUSIONS
The 24-month clinical outcomes of the positive
group in the intracoronary ergonovine provocation
test were relatively worse than those of the inter-
mediate group according to the results from theVA-KOREA registry. More proactive and intensive
clinical attention should be paid to VSA patients
with high risk factors including frequent angina
before angiography, current smoking, and multi-
vessel spasm.
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